Robin Sherrington

Robin Sherrington is the EVP of Strategy & Innovation at Xenon Pharmaceuticals. Prior to joining Xenon, Robin was the Director of Neuroscience at both Pfizer and Axys Pharmaceuticals.

Robin's career in the pharmaceutical industry began at Sequana Therapeutics where they were the scientific lead for neuroscience genomics projects. These projects led to a research and licensing collaboration with Parke-Davis. Sequana was then acquired by Arris to form Axys Pharmaceuticals.

At Axys, Robin led a multidisciplinary genomics team which included academic collaborators like Dr J Watson and Dr R Horvitz. The team's focus was on the discovery of novel disease mechanisms causal for bipolar disorder and schizophrenia.

In 1999, Robin joined Pfizer through their acquisition of Parke-Davis. At Pfizer, they were responsible for discovery and selection of novel targets for psychotherapeutics. Robin also chaired the integration of PD and Pfizer discovery pipelines.

Robin's wealth of experience in the pharmaceutical industry makes their an invaluable asset to Xenon Pharmaceuticals.

Robin Sherrington has a Bachelor's Degree in Microbiology, Biochemistry & Physiology from the University of Reading. Robin also has a Doctor of Philosophy (Ph.D.) in Human/Medical Genetics from UCL. Her research focus is on cloning Alzheimer's Disease genes.

Some of their coworkers include Chris Von Seggern - Chief Commercial Officer, Sherry Aulin - CFO, and James Empfield - SVP, Drug Discovery. Their manager is Ian Mortimer, President & CEO.